Gastrointestinal perforation in metastatic carcinoma: a complication of bevacizumab therapy

Eur J Surg Oncol. 2009 Apr;35(4):444-6. doi: 10.1016/j.ejso.2008.02.013. Epub 2008 Apr 15.

Authors

D Collins¹, P F Ridgway, D C Winter, D Fennelly, D Evoy

Affiliation

¹ Department of Surgery, St Vincent's University Hospital, Elm Park, Dublin 4, Dublin, Ireland. [email protected]

PMID: 18417314
DOI: 10.1016/j.ejso.2008.02.013

No abstract available

MeSH terms

Abdominal Pain / drug therapy
Abdominal Pain / etiology
Aged
Angiogenesis Inhibitors / adverse effects*
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal, Humanized
Bevacizumab
Carcinoma / complications
Carcinoma / drug therapy*
Carcinoma / secondary*
Confounding Factors, Epidemiologic
Female
Humans
Intestinal Perforation / chemically induced*
Male
Middle Aged
Wound Healing / drug effects

Substances

Angiogenesis Inhibitors
Anti-Inflammatory Agents, Non-Steroidal
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Bevacizumab